MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-07-2026
Theravance Biopharma Long Term Debt Current 2011-2026 | TBPH
Annual Long Term Debt Current Theravance Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 M | 10.7 M | 3.92 M | 6.75 M | 503 K | 9.87 M | 7.76 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.9 M | 503 K | 7.21 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | China |
 |
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M |  Israel |
 |
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.14 | 0.16 % | $ 653 M | USA |
 |
Eton Pharmaceuticals
ETON
|
65 K | $ 35.13 | 1.97 % | $ 945 M | USA |
|
Forte Biosciences
FBRX
|
416 K | $ 21.7 | 6.84 % | $ 281 M | USA |
 |
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Grifols, S.A.
GRFS
|
117 M | $ 8.14 | -0.67 % | $ 5.53 B |  Spain |
 |
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
320 K | - | - | $ 13.1 M | Canada |
 |
BioNTech SE
BNTX
|
45 M | $ 91.21 | 0.94 % | $ 22 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
4.56 M | $ 1.66 | 2.47 % | $ 442 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
3.04 M | $ 0.87 | 2.78 % | $ 145 M | USA |
 |
Compugen Ltd.
CGEN
|
521 K | $ 2.61 | -3.7 % | $ 244 M | Israel |
 |
Incyte Corporation
INCY
|
5.7 M | $ 97.69 | 0.63 % | $ 19.1 B | USA |
 |
Anika Therapeutics
ANIK
|
2.05 M | $ 15.09 | -0.33 % | $ 216 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | Canada |
 |
Ionis Pharmaceuticals
IONS
|
9.51 M | $ 75.94 | 1.17 % | $ 12.2 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.4 | 2.41 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
1.83 M | $ 1.6 | 5.61 % | $ 187 M | USA |
 |
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
4.16 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
294 K | $ 20.88 | 2.0 % | $ 2.66 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |